01.08.25 -- 2024 Made Us Nervous. Will 2025 Be A Happier New Year?

We’re ready to help usher your next drug into market! 2025’s first Outsourced Pharma Capacity Update provides a unique, virtual experience and the details necessary to find a CDMO for your specific timeline, volume, and production needs. Join us the last week of January as we draw the curtains on the industry’s best and give you complimentary VIP access to the resources available to support your success. Learn more and register to save your seat!

Process validation's stage 3a serves to reconfirm the assumptions made during design space development and is particularly pronounced for new modalities and emerging processes.

Partnering with an API CMO can help you navigate challenges you may encounter, ensuring you are using the best quality practices and minimizing delays in getting those medicines to market.

The complex biology of rare diseases creates unique hurdles, making it difficult to design and implement a drug development program. Explore the unique considerations for drug product manufacturing.

Delve into the complexities of scaling decisions to gain insights from biopharma developers' and CDMOs' mutual interest in achieving successful scale-ups and strategies for avoiding common pitfalls.

Discover the benefits of flexible pilot plant equipment. Seamlessly scale up your processes, optimize your formulations, and save costs with in-house small-volume production.

Examine several important factors needed to effectively support oral solid dosage therapeutic manufacturing and overcome the complexities involved.

A biotech with limited experience in the development and manufacture of high potency compounds sought to develop a process for producing a highly potent API used to treat an unmet oncology need.

Altasciences' manufacturing (CDMO) team provides tailored solutions for each phase of your drug development program. From discovery to market ― they’ve got you covered!

Lonza's Route Scouting Service empowers biotech partners to overcome the complexities of API development and bring life-changing medicines to market faster.

Jeff Clement, Executive Director of Technical Sales Drug Product Development and Manufacturing, outlines our global sterile fill-finish and lyophilization capabilities, investments, and expansions.